Spectral Diagnostics (OTCMKTS:EDTXF) Posts Quarterly Earnings Results, Hits Expectations

Spectral Diagnostics (OTCMKTS:EDTXF) announced its earnings results on Thursday. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.01), reports. The firm had revenue of $0.28 million during the quarter, compared to analyst estimates of $0.54 million.

Spectral Diagnostics Stock Performance

OTCMKTS EDTXF traded down $0.04 on Friday, reaching $1.02. The stock had a trading volume of 100 shares, compared to its average volume of 8,680. Spectral Diagnostics has a 12-month low of $0.47 and a 12-month high of $1.31. The business’s 50-day moving average price is $0.97 and its 200 day moving average price is $1.00. The stock has a market cap of $298.41 million, a P/E ratio of -9.27 and a beta of 0.04.

Spectral Diagnostics Company Profile

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.